Saturday 19 December 2020
The UAE’s Ministry of Health and Prevention (MOHAP) has announced the official registration of Beijing Institute of Biological Products’ inactivated COVID-19 vaccine in a major step towards combating the global pandemic. The registration of this vaccine is a decision in response to the application from Sinopharm CNBG. The announcement is a significant vote of confidence by the UAE’s health authorities in the safety and efficacy of this vaccine.
MOHAP, in collaboration with the Department of Health, Abu Dhabi, DOH, has reviewed Sinopharm CNBG’s interim analysis of the phase III trials, which shows the inactivated vaccine to have 86% efficacy against COVID-19 infection. The analysis also shows the vaccine to have 99% seroconversion rate of neutralizing antibody and 100% effectiveness in preventing moderate and severe cases of the disease.
The analysis shows no serious safety concerns.
The vaccine was granted Emergency Use Authorization (EUA) since September 2020 by MOHAP to protect frontline workers most at risk of COVID-19. The UAE is conducting the Post Authorization Safety Study (PASS) and Post Authorization Efficacy Study (PAES) of its EUA program. These ongoing studies show similar safety and efficacy profiles as the interim analysis.
The #4Humanity phase III trials have included 31,000 volunteers across 125 nationalities in the UAE alone. The EUA vaccination program has effectively safeguarded the UAE frontline workers. MOHAP's official registration of the Beijing Institute of Biological Products' inactivated COVID-19 vaccine leads the way to comprehensively protecting the population and responsibly opening the economy.